Physician

Seaborn Mcdonald Wade, M.D.

According to 2025 Medicare claims, Seaborn Wade, M.D. (NPI: 1265566772) practices hematology/oncology in the Richmond, VA market, with the plurality of this provider's patient population coming from Hanover, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER INSTITUTE INCORPORATED (NPI: 1730130980; TIN: 54-1066435) and primary practice location at 23116-3834.

Wade's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 689 traditional Medicare patients, billed 91,888 HCPCS/CPT codes, and received $1,964,712 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 695 prescription claims across 122 beneficiaries totaling $3,041,815 in drug costs, led by Revlimid (Lenalidomide). 2019 DME data shows 72 claims. Open Payments data shows 42 records totaling $1,606. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $467,750 to $3,041,815. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $6,051 to $155.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	917	140,260	$1,545,026
2016	892	150,177	$2,108,634
2017	847	146,442	$2,151,076
2018	853	169,564	$2,019,256
2019	834	135,872	$1,698,777
2020	823	160,156	$2,607,519
2021	788	134,652	$2,291,439
2022	773	153,126	$2,430,992
2023	711	128,042	$1,802,699
2024	689	91,888	$1,964,712

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	157	526	$467,750
2016	140	566	$546,476
2017	129	650	$991,407
2018	105	587	$1,435,051
2019	101	584	$1,840,761
2020	97	576	$2,058,315
2021	102	573	$1,994,624
2022	97	484	$2,025,118
2023	115	582	$2,189,116
2024	122	695	$3,041,815

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	137	$5,569
2016	N/R	182	$29,992
2017	N/R	24	$4,985
2018	N/R	44	$6,541
2019	N/R	72	$10,768
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	143	229	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	323	532	$59
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	95	133	$44
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	221	295	$12
96372	Injection of drug or substance under skin or into muscle	133	394	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	41	1,050	$662,214
Bosulif	Bosutinib	32	960	$598,364
Imbruvica	Ibrutinib	38	1,064	$597,614
Lenalidomide	Lenalidomide	24	672	$431,805
Pomalyst	Pomalidomide	18	504	$406,956

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	42	$1,606	US Oncology Corporate, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Seaborn Mcdonald Wade, M.D.?

Tedicare shows public-source Medicare data for Seaborn Mcdonald Wade, M.D. (NPI 1265566772), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Seaborn Mcdonald Wade, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Seaborn Mcdonald Wade, M.D.?

Seaborn Mcdonald Wade, M.D. is linked to VIRGINIA CANCER INSTITUTE INCORPORATED (billing NPI 1730130980) in the available physician profile data.

Does Seaborn Mcdonald Wade, M.D. have Open Payments data?

Seaborn Mcdonald Wade, M.D. has 42 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.